Form 4: Lexicon Pharmaceuticals Director Exercises Stock Options

Christopher J. Sobecki, a director at Lexicon Pharmaceuticals, executed transactions involving common stock and restricted stock units on May 13, 2025.

Summary

• On May 13, 2025, Christopher J. Sobecki, a director of Lexicon Pharmaceuticals, engaged in transactions involving the company's securities.
• Sobecki acquired 36,810 shares of common stock at a price of $0.
• Following the transaction, Sobecki directly owns 203,865 shares of Lexicon Pharmaceuticals common stock.
• He also disposed of 36,810 restricted stock units.
• The restricted stock units vest 100% on the first anniversary of the grant date and each unit represents one share of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it reflects insider trading activity, but the overall impact is likely minimal.

Key Dates

Keywords

Form 4, Beneficial Ownership, LXRX, Lexicon Pharmaceuticals, Sobecki, Director, Stock Options, Restricted Stock Units, Common Stock